Teachers Advisors LLC Takes Position in Conatus Pharmaceuticals Inc. (CNAT)

Teachers Advisors LLC acquired a new stake in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 46,014 shares of the biotechnology company’s stock, valued at approximately $265,000. Teachers Advisors LLC owned 0.16% of Conatus Pharmaceuticals at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Acadian Asset Management LLC lifted its stake in shares of Conatus Pharmaceuticals by 641.1% in the 2nd quarter. Acadian Asset Management LLC now owns 1,097,945 shares of the biotechnology company’s stock valued at $6,324,000 after purchasing an additional 949,785 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Conatus Pharmaceuticals by 28.1% in the 1st quarter. Renaissance Technologies LLC now owns 235,290 shares of the biotechnology company’s stock valued at $1,358,000 after purchasing an additional 51,590 shares during the period. Schwab Charles Investment Management Inc. acquired a new position in shares of Conatus Pharmaceuticals in the 2nd quarter valued at about $1,041,000. Bank of New York Mellon Corp lifted its stake in shares of Conatus Pharmaceuticals by 62.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 130,343 shares of the biotechnology company’s stock valued at $751,000 after purchasing an additional 50,033 shares during the period. Finally, Russell Investments Group Ltd. acquired a new position in shares of Conatus Pharmaceuticals in the 2nd quarter valued at about $679,000. 34.06% of the stock is currently owned by institutional investors.

Conatus Pharmaceuticals Inc. (CNAT) opened at $4.22 on Monday. Conatus Pharmaceuticals Inc. has a 52 week low of $1.73 and a 52 week high of $9.40. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.69 and a quick ratio of 2.69.

Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.08). Conatus Pharmaceuticals had a negative return on equity of 83.02% and a negative net margin of 80.98%. The firm had revenue of $9.57 million for the quarter, compared to analyst estimates of $16.06 million. During the same period last year, the company posted ($0.31) earnings per share. sell-side analysts predict that Conatus Pharmaceuticals Inc. will post -0.65 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://sportsperspectives.com/2017/11/20/teachers-advisors-llc-takes-position-in-conatus-pharmaceuticals-inc-cnat.html.

A number of brokerages have recently issued reports on CNAT. Zacks Investment Research raised Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, July 24th. HC Wainwright reissued a “buy” rating and issued a $17.00 price objective (down from $18.00) on shares of Conatus Pharmaceuticals in a research note on Thursday, November 2nd. Seaport Global Securities reissued a “buy” rating and issued a $16.00 price objective on shares of Conatus Pharmaceuticals in a research note on Friday, October 6th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $10.00 price target on shares of Conatus Pharmaceuticals in a research note on Thursday, August 3rd. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $16.00.

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Institutional Ownership by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply